The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer.
Aromatase, encoded by the CYP19 gene, catalyzes the final step of the conversion of androgens to estrogens. Given the critical role of CYP19 in estrogen synthesis, the potential influence of CYP19 rs4646 polymorphism on breast cancer survival, deserves further study.Genotyping for CYP19 rs4646 varia...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4368615?pdf=render |
id |
doaj-988097a5c0cc4caa934b0ab52fa357c3 |
---|---|
record_format |
Article |
spelling |
doaj-988097a5c0cc4caa934b0ab52fa357c32020-11-24T21:59:44ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01103e012153510.1371/journal.pone.0121535The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer.Xiying ShaoYong GuoXiaohong XuYabing ZhengJiwen WangZhanhong ChenJian HuangPing HuangJufen CaiXiaojia WangAromatase, encoded by the CYP19 gene, catalyzes the final step of the conversion of androgens to estrogens. Given the critical role of CYP19 in estrogen synthesis, the potential influence of CYP19 rs4646 polymorphism on breast cancer survival, deserves further study.Genotyping for CYP19 rs4646 variants was performed on 406 Chinese women with stage I-II and operable stage III breast cancer. Associations were evaluated between CYP19 rs4646 genotypes and disease-free survival (DFS).In premenopausal patients, women who are homozygous for the minor allele (AA) have a longer DFS compared with those carrying the major allele (CC or AC) (87 months versus 48.7 months; Hazard ratio (HR) = 0.56, 95 % CI = 0.318-0.985, P = 0.041). These differences were further demonstrated by a multivariate analysis (HR = 0.456, 95 % CI = 0.249-0.836, P = 0.011). Conversely, the same variant (AA) was estimated to be associated with a poorer DFS in postmenopausal women (AA versus AC or CC: 13.7 months versus 56.3 months; HR = 2.758, 95 % CI = 1.432-5.313, P = 0.002). Furthermore, the differences were confirmed by the COX proportional hazards model (HR = 2.983, 95% CI =1.494-5.955, P = 0.002).The present study indicates that CYP19 rs4646 polymorphism is related to DFS in early breast cancer and that the prognosis index of the homozygous for the minor allele (AA) may depend on menopause status. The findings are novel, if confirmed, rs4646 genotypes may provide useful information for routine management in breast cancer.http://europepmc.org/articles/PMC4368615?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xiying Shao Yong Guo Xiaohong Xu Yabing Zheng Jiwen Wang Zhanhong Chen Jian Huang Ping Huang Jufen Cai Xiaojia Wang |
spellingShingle |
Xiying Shao Yong Guo Xiaohong Xu Yabing Zheng Jiwen Wang Zhanhong Chen Jian Huang Ping Huang Jufen Cai Xiaojia Wang The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer. PLoS ONE |
author_facet |
Xiying Shao Yong Guo Xiaohong Xu Yabing Zheng Jiwen Wang Zhanhong Chen Jian Huang Ping Huang Jufen Cai Xiaojia Wang |
author_sort |
Xiying Shao |
title |
The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer. |
title_short |
The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer. |
title_full |
The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer. |
title_fullStr |
The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer. |
title_full_unstemmed |
The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer. |
title_sort |
cyp19 rs4646 polymorphism is related to the prognosis of stage i-ii and operable stage iii breast cancer. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
Aromatase, encoded by the CYP19 gene, catalyzes the final step of the conversion of androgens to estrogens. Given the critical role of CYP19 in estrogen synthesis, the potential influence of CYP19 rs4646 polymorphism on breast cancer survival, deserves further study.Genotyping for CYP19 rs4646 variants was performed on 406 Chinese women with stage I-II and operable stage III breast cancer. Associations were evaluated between CYP19 rs4646 genotypes and disease-free survival (DFS).In premenopausal patients, women who are homozygous for the minor allele (AA) have a longer DFS compared with those carrying the major allele (CC or AC) (87 months versus 48.7 months; Hazard ratio (HR) = 0.56, 95 % CI = 0.318-0.985, P = 0.041). These differences were further demonstrated by a multivariate analysis (HR = 0.456, 95 % CI = 0.249-0.836, P = 0.011). Conversely, the same variant (AA) was estimated to be associated with a poorer DFS in postmenopausal women (AA versus AC or CC: 13.7 months versus 56.3 months; HR = 2.758, 95 % CI = 1.432-5.313, P = 0.002). Furthermore, the differences were confirmed by the COX proportional hazards model (HR = 2.983, 95% CI =1.494-5.955, P = 0.002).The present study indicates that CYP19 rs4646 polymorphism is related to DFS in early breast cancer and that the prognosis index of the homozygous for the minor allele (AA) may depend on menopause status. The findings are novel, if confirmed, rs4646 genotypes may provide useful information for routine management in breast cancer. |
url |
http://europepmc.org/articles/PMC4368615?pdf=render |
work_keys_str_mv |
AT xiyingshao thecyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT yongguo thecyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT xiaohongxu thecyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT yabingzheng thecyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT jiwenwang thecyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT zhanhongchen thecyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT jianhuang thecyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT pinghuang thecyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT jufencai thecyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT xiaojiawang thecyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT xiyingshao cyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT yongguo cyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT xiaohongxu cyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT yabingzheng cyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT jiwenwang cyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT zhanhongchen cyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT jianhuang cyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT pinghuang cyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT jufencai cyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer AT xiaojiawang cyp19rs4646polymorphismisrelatedtotheprognosisofstageiiiandoperablestageiiibreastcancer |
_version_ |
1725847412546732032 |